FLEXIANT
Flexiant , a leading international provider of cloud orchestration software, today launched Flexiant Cloud Orchestrator version 4, aimed squarely at helping service providers increase profit, revenue and growth from cloud services.
451 Group, Research Director for Infrastructure Software, Michael Coté said: “It’s clear that there’s a rising demand for public cloud services, creating a pull from service providers for cloud enablement platforms. The challenge for service providers is to simultaneously stand up robust cloud services and at the same time establish differentiated services for which service providers can charge more than just commodity cloud prices to rise above cookie cutter approaches.”
George Knox, CEO of Flexiant, said: “Service providers need to get ahead on the cloud battleground. Often, however, they are apathetic, apprehensive and sometimes defensive in their approach to cloud with some strategies actually putting these service providers on the back foot. Flexiant Cloud Orchestrator solves these issues by helping service providers develop their own unique services to differentiate and lead through innovation to generate more revenue and accelerate growth.”
Flexiant has opened up version 4 of Flexiant Cloud Orchestrator to deliver a new platform that supports easy integration with third party technologies, as well as future support for OpenStack. This gives service providers access to a wide range of third party plugins allowing them to tailor a vast arsenal of differentiated services with which to secure new customers and revenue stream. As the only management software needed to power a cloud, service providers can now compete against Amazon’s ease of use, while differentiating in the cloud industry with customizable software that allows them to deploy solutions right for their customers.
Tony Lucas, SVP Product and Founder said: “Central to offering a complete range of cloud services is our new Plugin ‘Trigger’ technology which opens up our platform. It allows service providers to differentiate by applying customization to core business logic and enable ecosystem partners to tightly integrate with the platform through both inbound and outbound APIs.”
“The Plugin Trigger technology is the landmark feature within Flexiant Cloud Orchestrator V4 because we now offer the ability for service providers to easily modify and extend their platform based on their own needs, increasing the ability to differentiate, and to deliver the services their customers want.”
Flexiant also announced today its product roadmap that includes support for OpenStack in Summer 2014. Flexiant will give service providers a rapidly deployable, functionally rich, service provider ready solution based on OpenStack, extending its existing similar capabilities for VMware vSphere and Hyper-V as well as its continued direct support for Xen and KVM.
Knox continued: “By opening up our platform and announcing OpenStack support, we are delivering unparalleled choice to make it even easier for hosters through to large telcos to build and launch innovative and commercially viable cloud services quickly into the market.”
Version 4 features beyond the Plugin ‘Trigger’ technology includes:
1. Direct support for the Chef configuration management tool from Opscode, including integration with Flexiant’s Blueprint technology, Bento Boxes, enabling powerful new use cases.
2. General availability for Ceph, a distributed block store storage system designed to provide excellent performance, reliability and scalability, ensuring Flexiant now supports all common storage modals.
3. Improved Billing System enabling both subscription and metered billing for services providers and their resellers
4. Enhanced ability to on-board customers based on their geography, language and billing requirements
5. New payment provider plug-in to integrate with multiple payment providers
6. Multi-tiered billing systems to solve complex billing scenarios
7. Context sensitive Help within the UI that can be branded and white labeled as required
Knox concluded: “Our goal at Flexiant is to constantly innovate to offer service providers the solutions they need to do the same. V4 changes the way service providers can deploy cloud services, easily integrate with third party technologies and customize and deploy solutions right for their customers. We are enabling service providers and our partners to help each other win the cloud war.”
- ends -
About Flexiant
Flexiant provides cloud orchestration software focused solely to the global service provider market. Flexiant Cloud Orchestrator is a cloud management software suite that arms service providers with a customizable platform to help them turn innovative ideas into revenue generating services quickly and easily. With Flexiant, service providers can generate more revenue and accelerate growth, compete more effectively and lead the market through innovation. Vendor agnostic and supporting multiple hypervisors, Flexiant Cloud Orchestrator offers a customizable platform, a flexible interface, integrated metering and billing, reseller capabilities and application management. Flexiant gives service providers the ability to develop, launch and bill for new cloud services quickly.
Flexiant has been named a Gartner Cool Vendor in Cloud Management, received the Info-Tech Research Group Trendsetter Award and called an industry double threat by 451 Group. Flexiant is now a Dell certified technology partner . Customers include Computerlinks , ISONNET , FailProof Technologies , ITEX and NetGroup. Flexiant is also a key participant in the FP7 Consortium . For more information visit www.flexiant.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131104005160/en/
Contact:
Octopus Group
Anne Ligory / Lawrence Benfield
+44
(0)8453 707 024
flexiant@weareoctopusgroup.net
Tier
One for Flexiant in U.S.
Sue Parente
sparente@tieronepr.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum